LBPH - Earnings call transcript Q2 2024 | Longboard Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Longboard Pharmaceuticals Earnings and Corporate Updated Call.

As a reminder, this conference call is being recorded. I would now like to turn the call over to Brandi Roberts, Longboard's Chief Financial Officer.

You may begin.

Brandi Roberts

Thank you, and good afternoon, everyone. Welcome to Longboard's conference call and webcast where we'll be providing a corporate update, including results from our LP659 single-ascending dose study.

statements I and to statements anticipated webcast company, guidance. without today, this everyone about timing begin of commercial including call potential opportunities clinical conference will limitation, line and we design would candidates, trials, remind like that the our of Before product the top the data, about contain financial forward-looking and actual risks results subject statements to and uncertainties could are differ. to cause These that those our from in or discussed the outcomes reports Factors by to forward-looking or filed that could actual such materially implied cause in results differ greater most with expressed statements are detail SEC. in recent or Please over CEO. information to or our in hand this publicly opinions results new note of date these reflect the I'll light call undertake of of Lind, forward-looking President call, the that Kevin statements only and forward-looking as revise no statements release future any these and the revisions that, Longboard's of we to events. With to obligation Kevin?

Kevin Lind

Brandi, and and of of selective financials month. is on seizures motor Brandi asset, number our other our to a Encephalopathies, X Lennox-Gastaut very Thanks, organization LPXXX, I'm providing achieved that DEE start Phase Bexicaserin what top incredibly were proud time then by top the Longboard. I'm for June, accomplished update XXXX Q&A. We we very will today a exciting of medications Ib/IIa across going an X of or highly X-HTXC line busy on our Bexicaserin, much and participants. DEEs. joining a give kicked countable update a on extremely from Bexicaserin receptor us before portfolio. it in and had off and to off in entire then Epileptic to lead we we We an of Developmental Dr. in on approximately a the positive provide for update very evaluating median highly open over PACIFIC Dravet, in study, during specific other an hand a with have and Then the everyone participants anti-seizure in agonist and Kaye to and refractory XX% you reduction data what call to thank pleased year

analysis First, study open-label we placebo sustained participants shared Bexicaserin. successful an with a favorable approximate our safety PACIFIC, of over all demonstrating well titration and X-month as extension interim to an tolerability of continued of response of period as on our

DEEs designation Phase our completed associated seizures meeting. And with the age II of X. for granted third, we down end Breakthrough Second, of to Therapy the FDA

are is of founding and working DEEs. tremendously underserved. to which We these Data the PACIFIC this for Longboard. of rewarding have receive what we achievement Both since to and thesis designation first and provide our been and support company been Breakthrough have access only Therapy believe designation most equitable the patients The treat to towards, DEEs more broadly we strengthen that are the

To advocates design III our that committed are overwhelmed been forward all physicians. a difference DEEs. those living to DEEs global program. from our excitement to have for making of end, and caregivers, with support by We outpouring Phase study We're in innovative with and the we moving

goal to of with in with the FDA to so an for unmet the have population medical pleased opportunity optimized this We are the collaborate the need addressing tremendous manner.

We start pivotal intend study studies, to include DEE will I'd some for on Investor modulator. switch other receptor XX. With to and to second our Analyst September III program this be and III was GPCR to Phase an designed DEEs. discovered our all second that, Lennox-Gastaut was centrally created our like provide include we'll SXPX,X research LPXXX predictive been and Phase in half syndrome the year, considered to acting team, that early Dravet studies with a LPXXX X SXP highly understood We at initiate selective are of modulator additional that over same on Day of to into data the optimized etrasimod. details same upcoming clinical and receptor etrasimod. the well and generally program, SXP shown the stage one expeditiously which X asset, preparing of team receptor and clinical be the differentiating Arena's has LPXXX, world-class built effectiveness. modulators by are characteristics a will

learnings very here. That, CNS been oral interesting sclerosis orphan conditions. models lymphocyte its and have the these high suggesting up of potential modulate human It lot similar LPXXX indicating PX, think has could is for substantial, meaning directly commercial and a LPXXX models, SXP that attractive works market have We modulators additional receptor be to treatments absorbed and is already shown efficacy applications, from space centrally promising opportunities. I&I coupled LPXXX in in doing work it generating receptors, targeted several indications preclinical demonstrated translational sclerosis. glial crucial with a receptors. therapeutic CNS opened we taken rapid and action, shown the effective In SXPX and making SXPX revenue and of it onset role and It with play SXP no manageable nervous Its selectivity multiple has in in cell The for a minimizes more its on profile primarily effectively results mouse CNS modulation, approach. offset clinical conditions. immune in a systems. significant studies orally, bioavailability, impacts settings. and when SXP high enhancing multiple in potentially has receptors it significant which off-target have impact to effects, SXPX exhibits preclinical various

LPXXX's of turn properties range that, advancements potential a SXP we be unique understanding with the orphan to addressing that Randall. on a best-in-class based neurological CNS-focused to in believe it disorders. With provided of over SXPs, our However, I'll

Randall Kaye

LPXXX delve receptor by thanks, Good broad with like Today, how functions applicability SXP and modulating I'll treating orphan promising into LPXXX, on SXPRX. presenting rare our conditions. I'd afternoon, various Kevin. neuro in selectively be modulator to

the functionally SXPs, agonists these subsets binding of work receptor, lymph reminder, egress to specifically, from a SXPRX, induces normal antagonizing as This nodes. disrupts the degradation. internalization just in So of and receptor by LPXXX more lymphocyte the

of lymphocytes, by effects may and expressed its mechanism LPXXX receptor LPXXX myelination. inflammatory to and has the minimizing astrogliosis activation astrocytes that damage. X reducing body's is a in is in function. reduce organ intact. cells In neuroinflammation remain this surveillance, important SXP defense microglial the thereby and So and are to role oligodendrocytes, play the the release while survival. been tissue expected These cell glial shown the reduce on support ensuring neuronal cytokines, enhance SXPX of does maintaining And decreases what's still migration immune In CNS,

in does or the profile highly that to SXPX liabilities SXPX, associated coupled to as not at the and neuroprotection SXP safety of are activate is activity. in and bind as decreased importantly, potential SXPX neuroprotective class, generally the includes the activity known potent And inflammation humans next CNS. with selectivity of and nervous active not receptor retaining fibrosis considered to LPXXX mediating blood SXPX vasoconstriction, well with agonist who brain the has SXP It LPXXX have SXPX that effects. is receptors little be the anti-inflammatory a been the SXPX. some and the X of central while decrease On or integrity. potential barrier receptors directly X X in are There is slide, are system. its enhance and X

effect. SXPX agonist greater is LPXXX to target the diseases CNS-related slide, a precision. next the was potent designed therapeutic to LPXXX be receptor to be the for and next-generation its most at SXPRX crucial potency is On internalization with designed agonist the

LPXXX its to for fingolimod. examples modulators, so tested as beta-arrestin potent ponesimod coupling internalization siponimod, when So well of G ability both total most of promote such ozanimod, mediated as when as think the all CNS-focused of emerge by the proteins you approved as and SXPRX other SXP

So importantly, beta-arrestin triggers antagonism. causes LPXXX and G Beta-arrestin signaling over protein internalization functional preferentially signaling. signaling

of effects therefore, selectivity furthermore, greatest first contributes to with this protein SXPRX is a then bradycardia, SXP The And selective SXPRX. G signaling contributes demonstrated receptor dose to So modulators. for clinically LPXXX the class. the the over seen this less anti-inflammatory

alone. activity at beta-arrestin side signaling when this seeing of screen the on the tested You're right-hand for

So it pioneering from SXPX with potential and autoimmune internalization treatment diseases. as positions LPXXX's managing CNS-related potency at a significant

cells cells killer LPXXX the and next B on On effect slide, reduces monocytes. natural without and T circulating

is T immuno-surveillance. infection. with the in-vivo potent from and LPXXX the alternative This compared X strain, weeks, rats that EAE for Those data dosed populations. you are cells This activity. B-cell It for to seen I'm So on demonstrate combating that is responsible thus, as this are rates. and in side showing vehicle is the of LPXXX lowers what's the left-hand a effectively uses this preclinical model. EAE

function their and class Importantly, been the effects cells. them call disease. T cells T-regs in that anti-inflammatory and have autoimmune regulatory increases proportion we'll beneficial of T-regs to CDX found total over a the cells, T of are LPXXX be neurodegenerative has

notable, monocytes, and I not a before, on have LPXXX this significant described cells. cells effect of indicates does selective immune natural modulation it's Now killer on

in frequency. clinical mechanism T-reg class, data are action a efficacy. selectivity in-vitro therefore, drug of These model, preclinical with LPXXX effects expected that B increase T confirm in improved reduction promoted preclinical profile while this of LPXXX So cells, the significant suppression maintain increased CDX-positive and market cells a and an consistent to the of of is these

after first-in-human the design sorry, day clinical of is So objectives X administered a discuss in trial. X, subsequent what and fast, a I is XXX clinic attention ascending overnight XX. its then And administered I'm cohorts SAD on for day on by to X, Formulation to I on of single as administered the data. Phase adult day -- the washout and cohorts, the X, and followed X SAD fasting, in and healthy -- formulation just call This represents and X, to this This well and study next X studies, have after formulation X, administered is they're a It's as X. subsequently overnight discharged study. following we're Phase of And Cohort an formulation your stay X day X-week on and a the administration they're their trial going call a volunteers. they discharge slide We they're dose. washout day formulation they X key to they're X an

determine in single to PD dose. tolerability XXX determine to to profile of So ascending PK of the the in ascending metabolites profile dose the its doses and key the of LPXXX a study safety LPXXX of objectives and ascending single are assess a single and

the severity. going the Phase I'm generally the was study We'll focus of events give of next, well were by tolerated to and aspects mild LPXXX safe adverse study. overview. first an So on All I safety participants.

is which adverse period. throughout low in consistently The the study a nor no first-dose serious adverse were no to led often notably, the observe treatment-emergent during duration. rate impact study events events instances of there of was we heart bradycardia, did Importantly, treatments. discontinuation concern study similar the on And

ECG for showed tests, also assessment abnormalities, no we findings no of no safety the showed this including block, cases including functional adverse atrioventricular cardiac normal populations, no in pulmonary and treatment pelagic abnormalities highlighting assessments infections spirometry, Our study echocardiograms indicating regard. normal, were the no reported, with no among adverse event profile observed favorable function events,

So demonstrated safety LPXXX profile. encouraging very a overall,

Let's get to good the stuff.

formulation the So the decrease we're A, just where from as well well point, XX% a just an to a to as the just evaluate change single ALC This percent dosing. at drug's right drug's note as going absolute to reduction effect going we're important dose XX.X%, XX.X% time show here's not highlight continue to ALC, overview mechanism X about we're as we're an placebo to XX-hour see with suggests in indicative that reducing of is X.X%. is study, dose optimizing of see effect is as the varying and of safety parameter you, as reiterate changes showing a formulation, mean reduction counts on formulations we look a percent It's LPXXX X, X.X% I'm C doses you assess just has profile. modulators. OC, important different presenting to as that in effectiveness This of a is of over that looked post-dosed. The lines a this period. pooled Dose D lymphocyte expected. that to Further doses action a It's well greater analysis in to to of reductions. crucial [ALC]. starting and That's hoping and placebo at on-target and coat LPXXX that as effects pooled And in data anticipated dose SXP strategies. This here lymphocyte reduction; Dose studies higher is our in continuous our dosing X.X, and cohort lymphocyte I'll potential baseline functioning it group. mean graph the is as in to B, will is represent with remind I'll at formulation-dependent the effect long-term the

get the where do So innovation of I&E other we conditions. what opportunities by XXX The characterized promise fingolimod of that could neuro, due its and and point, does this ability B What to now space pathology do progression. selective autoimmune, target. potential on proteinopathies. indications studies in and neuroinflammation and its the outlines we disease information from T been to to broad the all and/or and the continuing mean? we in in and is we primary condition reducing that role disease here? of development mods. of outcomes. To in immune lot these the approval action together to a the cells There's are unique Each slide approved bring list preclinical potentially targeting end, thereby since clinical LPXXX This start and and modulate of of the indications to cell How T grow. inflammatory behavior, XXX this in is promoting have its go conducted better SXPRX areas shows of potentially B areas inflammation X interest: the

results study, XXXX. And I'll that are it of the MAD set the turn conducted that there's order best a forward a review our can practical preclinical support be indication to clinical will to to Phase to decision, over and I where feasible. that is studies that with expect believe be need, we see there In are of clinical in initiate we our unmet where and medical to in finalize strong continue financials. for anticipated high whereby We that, Brandi first want LPXXX which path an and/or quarter to data the

Brandi Roberts

runway, take Thanks, approximately Phase this reflects forward. We $XX our our programs of QX Randall. results, I'd III and in bringing a our like cash to cash color investments, the with second to quarter on and million quarter. provide the and about cash a program our million for opportunity this bit more for for scaling ended burn strategy $XXX

first our Our were expenses our Bexicaserin to quarter second quarter were expectations. to amount R&D These expenses a in due expenses and accordance LPXXX. higher related primarily than smaller with internal activities, increased for

open-label significant continued prepare Bexicaserin, For had program. study to Phase extension III as we activities for our for as activities well our

expect the our best-in-class to to world-class our our make expenses continue That of the advantage studies DEE community upwards health as tremendous continue broader unmet building LPXXX. We ones acceptable our for and commercial Bexicaserin Bexicaserin additional caregivers, roles team a out and to need make educate portfolio trend III order characteristics on and opportunity pace program our slightly that potential exploring means their patients, focused infrastructure XXXX organization, our on the and care that's with we loved specialists. and sure taking and for will our clinical to progress non-clinical at organization, global and the during clinical interact to elucidating scaling DEE community and of differentiate to to Phase the build-out continue in about

every very are for for want managing ahead XXX. We excited about resources We We of seriously. opportunity the matter. very take to responsibility our dollar Bexicaserin us and

we program, level are we action for best of consider risk/reward and constantly shareholders. studies plans and company of for either the for we So course believe whether the our that the when is additional evaluating spend

call, in that June vision Our ability of us approximately XXXX, is to have into and we cash the execute $XXX continue the investments gives on XX, value and our to to million goal build as the from turn the to remarks back afternoon's call to this now I'll concludes for XXXX. This prepared open Randall. Q&A, and where and Operator? the line Kevin I'll be operator by the rejoined

Operator

first your question, [Operator with Instructions] Chico Wedbush. For Laura

Laura Chico

I'm that Bexicaserin could question efforts little X on you expand with sizing then bit a to Bexicaserin III With have Phase if on the the pivotal X I the to just program, I'm respect be of and of respect just XXX. just wondering thank commentary. to any number all that on minimal of to there for studies. certain basis. With respect need a DEEs you, respective represented numbers kind just types Randall, the wondering XXX, are if of patient

you could in little terms steps. of bit the Just indication next matrix kind walk if a selection for wondering of through decision

Kevin Lind

to for sure On we the Phase III we want program at make Bexicaserin, not it all piecemeal. out roll right time, the

the us go can mods the help can has is other the in cost-efficient interesting elucidate Can preclinical a can regards patients, Day of It's And manner we're to go your at so after matrix, from the studies, I'm X around we mods scheduling fulsome And happy this a really from XX. With been as as the while. this reward R&D can science. can find we've look we for do could Is it. because that to this question And thing that September forward to manner. translational I&I. we commercial commercial Do over-time, the other something indications a area, generated well that piece things. time-efficient on a this take the a expanded on translational what we to talking that disclosure risk something learnings Is other for feasibility, is we of second and we combination clinical last planning indications data to then like all to we competitive potential the It's data of attractive? models we're side. decision landscape do? And the is on about glean we after. look do the The opportunity. in the enroll

the triangulating did we we to of started indications. IPO, And of I we a couple kind when around so think when talking folks were

preclinical we about learning have more lens literature searches models, additional As that has as we really done run as have XXX, and it opened wider. additional we through have progressed

And help final the where make steady have But indication of a to are how that sense state. we we think we in what we the it's at us want little today decision. to that so see good see pick until is performs premature a MAD drug to I

IPO, And expanding would to indications. is and the interesting did this so it about while earlier asked when thing be we would out the now. have indication, we had lot were little to continuing potential that me would a you I bit the said we're frankly, and we our if hoping have But roll selected indication by learn a done really when

is probably closer and as answer or it we'll MAD or Phase sense move end II. Does my Phase out So to the after roll question? your our MAD the to closer of II we expected that

Laura Chico

Yes, it does.

Operator

Beatty Our Baird. Joel with next is from question

Joel Beatty

The Bexicaserin. the DEE think destination question is breakthrough market on Are from how your is that? first is investors since getting And the opportunity? share research I most able common large about you been one on the I've therapy anything to

Kevin Lind

Yeah.

bit little a talk more about in that we'll So September.

where saying clinical trials we're trying tremendously We're over number with a of who very access the Lennox-Gastaut standard address genetic I to migrate other will And a life. market what course say feel big. we care. have the there's to have to we think a diagnosis what the we don't to DEEs. of think of excited and number plus to patients look comfortable their potentially don't are the exciting. is or DEEs have that opportunity us, by make of patients But We're and have is able learn. patients to of diagnosis about to for left will still be not that really latest latest We're do indication is who a access to a lot one who trying today, we double-counting their sure including at the

numbers, to that there's So something more a that indication. real with think in designation but opportunity that we here exact do come to on

Joel Beatty

And then a on XXX. question

presented slides quite or you'll anything the like able is the Are in today, tested large On those formulations that share MAD least formulation about much formulations. formulations X looked how X at testing be study? different to a difference it there was with what in you

Kevin Lind

I study, formulation of triangulated the MAD we some have too. think in on variation

the slightly variability. you less plasma Obviously, impact on much formulation adjust better but margin, has on too the Formulations the we and think will gets see can potentially lymphocytes. into

And over something. the going MAD. And is pass so to too Randall formulation forward add to I'm it path to for the

Randall Kaye

Yeah.

content target where a of from Just and wanted a findings. we was that reduction counts. in is the range. development point show us formulations to add SAD. absolute We to terms to have got were to XX% That's doses great in the to in be lymphocyte standpoint early both in preliminary The XX% an

keep early product. in ascending multiple thing get absolute important decrease that, benefit an lymphocyte in would terrific best anticipate But with one to continue multiple in to mind that counts to both of are doses, will a dose is these So study in the decrease formulations. the findings

Operator

Evercore. question Our next Gavin comes from Clark-Gartner with

Gavin Clark-Gartner

of Bexi the doing and form question. follow one I'll one SXP

just Bexi, DEE on just the aligned sounds it could already? with discussions potential regulators with of comment First, since path on broad global on status FDA for clearly the you the the you're like

Kevin Lind

this do Randall, you one? to want Sure. take

Randall Kaye

details Sure. talk all about September. global Well, the We're in we're about III planning a that going program. Phase to

are thinking initiated designation have global and share globe, of authorities will other anticipate breakthrough and other the Therapy discussions the information One and regulatory reasoning regulatory authorities. the our our aware our or that that discussions, each precedent designation do areas of Breakthrough -- behind talk believe would part the with We set and do not, as with across it they will therapy across. it. in We

a similar So fashion. positive regulatory we discussions will other would expect in authorities go that our with

Gavin Clark-Gartner

was the dose just at on impact, what half-life heart of saw and where or the impact humans there? what rate the And you in largest the X the I'm SXP, is wondering XXX QTC the ALC

Kevin Lind

Yeah.

to it pass me Let Randall.

Randall Kaye

Yeah.

numbers were did a comment finding. not note that of made the heart in We there also tested. can't I I did abnormal on see clinically formulations see. in decrease the QTC normal. changes ALC no the EKG all not numbers, any rate and heart So significant question on we they rate because a were

QTC not. prolongation you're implying do any we think we and did I see

Kevin Lind

Half-life.

Randall Kaye

in dose that have discussion ascending with dose. see be or forth. positive PK typical implying just after negative such Tmax, The the here. want half-life parameters AUCs not you I'm multiple ascending a talk dose a a only have the misleading. we there's can depending half-life until single general, Cmax, They as that wait do a is to to so you until better the multiple think about half-life sometimes on study. you product, and way Half-life, I that

Operator

Our next comes from Patel Riley with question B. Kalpit Securities.

Kalpit Patel

mentioned before You the you you if included DEE study. DEE the I component? comment how have you address that other an can next into month, guess other event component aiming that are LGS to many in different DEEs

Kevin Lind

study think on I the patients. a but we And almost XXX going study be it's question, study a It want actually be clear The Lennox-Gastaut though, includes DEE is that DEE to reverse. is that great truly to that. includes a very Lennox-Gastaut.

potential DEEs how there. continues will to yet many disclosed DEEs been number in as more of haven't generic go be We up has The data generated.

study, this we that R&D So have did around out the of that us Day, the you the we in study something? DEE roll and number do a a DEEs study but can in mind, we to want population add number as see gives XXX PACIFIC number probably that we'll forward. Randall, we move entire in comfort

Randall Kaye

was a the disclosed XX it So individual know said asked DEEs But and onesies before, PACIFIC that patients I haven't study. in we the And study. there bunch of twosies. from when we are

of conducted forward And amount you exciting move that expect study. math, details DEE population. to in We'd in PACIFIC a and the we'll So through for do stay the in we to significant then. you heterogeneity imagine different that DEEs want in a September, is much the that tuned observed larger if go more could study some there

Kalpit Patel

we month, then sort data there follow-up what open-label late-breaker data cutoff seen. is what have or Is And the as analysis data are extension Okay. same more next for of the we expecting?

Kevin Lind

Yeah.

well that in-depth So have reduction safety the so we of be data presented data countable cohort as will full data a set time that and presented, is X-month the for the The will it provide that an much at in there, percent reached opportunity of that seizures point have that to investigators. open-label lot for motor us gives study, the more that allow point. of potential a as investigators. which has the cutoff, a as beauty potential to was that We pleased will in were it Europe, see great and European extension with our it's us start engage it to to is this accepted our with discussion

Kalpit Patel

guess, And one clinical the XXX. it then you I one it's stand do hold Okay. partial And already guys not need do if where for last to there? what on resolve resolved? you

Kevin Lind

to partial So hold, place, to plan with the a with and multiple move the our clinical regards forward ascending it is study. hold complete to is still partial for the in response the with will coupled proposal clinical dose that be

And resolving that so soon. we would anticipate

Operator

David Hoang from Citigroup.

David Hoang

ask just first, about, indication So again, to wanted I the selection.

And really I maybe to let's or be across you after single a having try partner and areas. I one we indication say, just potentially indications? it about access even potential had the one as, follow-up. more you to you I guess, thinking think then had think indications going few and of than could about indication larger different therapeutic the slide and Should up showed quite a number selecting a

Kevin Lind

are I indications many Phase to think potential could we decide waiting we II. how take into

one to look to on And so life continue way. be that the at we're along that bit limited. a challenge with everyone LPXXX going is the patent The little honest is to

plus patent to extension. XXXX have composition term matter We

we us to So mean bigger orphan but in it's property sure build as portfolio. the go out indications the after broader, indications, we we want That right doesn't we continue think make can't helping to it way. about entire about intellectual think

David Hoang

molecule. And then I just the wanted to ask of quickly safety on the profile XXX overall

would ocular cardiac seeing to other physiological about systems, not and the a there. lot SXP But you talked other anything about molecules compares think say You you such, class? XXX in if and how

Randall Kaye

you of early impact a pulmonary I profile of actually finding, is mods, the I closely, the part boring drug. more finding. go look on have on. went a safety but to edema not It's through ocular just not that not is a through, uncommon function the macular the system, uncommon what at In cardiovascular

It's obviously, and study. systems dose what our initial had that an ocular ascending a very but monitor caveat. infections see it's continue, mentioned plus ascending we I are the study. set, not It's dose single seen, organ abnormalities mods. the single did a interesting the but findings of is pulmonary end typically is aspect this So We'll to cardiovascular other is a the big just at in data very,

but reduction, You do to want have to of selective. be kind lymphocyte want you

You down immune and shut don't surveillance. immune to totally the system want

infections. opportunistic event continue and to well. for for and monitor no I'm it's that that to follow this set, So infections infections. as we'll We saw important the potential in data adverse

Operator

Suneja from Yatin Securities Guggenheim

Yatin Suneja

Maybe X me. from

terms In missed there if one DEE for endpoint talk the that specify second X. And endpoint, you on would you might of then DEEs? I what then different So you the want you it. be observing? of that's are SXP about that's one. food a across the subsets molecule. sort can those go will effect to of broader that could Is specifically, see how And the harmonize in maybe you indication, you MAD have if So the helpful.

Kevin Lind

the Do you take one? want Sure. first to

Randall Kaye

Yeah.

in commonly been can as seizures. anticipate in in that, this on surprise endpoint, have anticipate that authorities medications unanticipated plus across primary call, has but this imagine, would that the or we as something anticipate likely study this global the more studies. that a I regulatory approved go the harmonized that is I been you utilized other So was been outside having through space. with a with an this utilized research because in ongoing discussions used be that have detail being U.S. lot endpoint study subsequent the we wouldn't PACIFIC can again, countable the motor be we'll in endpoint endpoint We that would our our

Kevin Lind

Then on XXX effect? food

Randall Kaye

We study. I and are studies, don't single a don't done Those study. of comment best effect multiple component because that separate remember food as I ascending if in be analyze dose the can't a today ascending would

Kevin Lind

look and answer final we'll eye dose cardiovascular Obviously, the we're pleased first We important development the and think whether that. would reduction suppression, used XXX. see sustained either, the want not then we Obviously, see perspective able We're little that dose to MAD, to to we like through the incredibly immune look of tends to ascending based keep lymphocyte the see risks. as well see in of a have the the want a didn't that a do way to what set that that avoid as with the space. tends unknown. that to be lymphocyte at have would over-time, going broad But single to And to like the from better all We're That's monitoring the going we to foremost. safety. on combination on data obviously the Obviously, side, will to cardiovascular at. an were have titration to get we continued obviously for Etrasimod mods or didn't is do reduction in SXP to see significant MAD? have which I MAD. other on bit to folks

Yatin? that So those MAD be we for the were molecule the would kind answer question, move make from decision to your things forward. Does looking of the to the

Yatin Suneja

Yes.

Operator

Q&A back Lind our over the conference Kevin to concludes session. That remarks. Mr. now closing for will I turn

Kevin Lind

want patients, great continue and clinical enthusiasm the how thank sharing the the differentially everyone for Have think can execute, day. community and serve in in Longboard We'll best to today story. call I we a for about and our stakeholders. deliver our to joining development and

Operator

call. gentlemen, all and that Ladies you joining. concludes today's for Thank

may You now disconnect.

Longboard Pharmaceuticals (LBPH) 1 Aug 242024 Q2 Earnings call transcript